Advertisement


Boris Sepesi, MD, on NSCLC, TILs, and Overall Survival

2017 Multidisciplinary Thoracic Cancers Symposium

Advertisement

Boris Sepesi, MD, of The University of Texas MD Anderson Cancer Center, discusses immune cells within tumors and the potential role for checkpoint inhibitor therapy in the neoadjuvant setting of locally advanced lung cancer (Abstract 7).



Related Videos

Lung Cancer

Shraddha M. Dalwadi, MBA, on Stage I NSCLC: Racial Disparities in Treatment and Outcome

Shraddha M. Dalwadi, MBA, MD Candidate in the class of 2017 at Texas A&M Health Science Center, discusses findings from a SEER database study that showed African Americans and American Indians with stage I non–small cell lung cancer were less likely to receive definitive treatment and had lower odds for survival (Abstract 9).

Lung Cancer

Zofia Piotrowska, MD, on NSCLC: Resistance Mechanisms

Zofia Piotrowska, MD, of the Massachusetts General Hospital Cancer Center, discusses heterogeneity and variation in resistance mechanisms among EGFR-mutant non–small cell lung cancer patients with at least one postresistance biopsy (Abstract 1).

Lung Cancer

Martin J. Edelman, MD, on NSCLC: Final Results of a CALGB Alliance Trial

Martin J. Edelman, MD, of Fox Chase Cancer Center, discusses study findings from a phase III study of celecoxib in addition to standard chemotherapy for advanced non–small cell lung cancer with COX-2 overexpression (Abstract 2).

Lung Cancer

Kamran Ahmed, MD, on Lung Cancer, Radiation, and Immune Checkpoint Inhibitors

Kamran Ahmed, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses results from a small study of pneumonitis in patients who received thoracic radiotherapy within 6 months of anti–PD-1 therapy, anti–PD-L1 therapy, anti–CTLA-4 therapy, or some combination of these drugs (Abstract 10).

Lung Cancer

Richard J. Cassidy III, MD, on NSCLC and SBRT in Older Patients

Richard J. Cassidy III, MD, of Emory Winship Cancer Institute, discusses results from a multicenter analysis of stereotactic body radiotherapy for early-stage non-small cell lung cancer in patients 80 years and older; the patients tolerated the treatment well and had excellent estimated rates of 5-year cancer-specific survival (Abstract 111).

Advertisement

Advertisement




Advertisement